CLINICAL TRIAL: BRAIN DOPAMINE FUNCTION IN ADULTS WITH ADHD

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 本研究旨在探讨成人ADHD患者脑内DA系统的参与情况，并评价长期服用兴奋剂哌醋甲酯对ADHD患者治疗12-14个月后脑DA功能的影响。当前提案中假定ADHD患者DAT代偿性降低的假设是基于我们在未服用药物的ADHD受试者中的试验数据(见第三节)。我们将遵循PET扫描的研究设计，正如我们在IRB#353中所做的那样，在该研究中，我们成功地登记并完成了从未服用药物的ADHD受试者的研究。在目前的建议中，在完成PET扫描后，ADHD受试者将返回他们的转介医生那里进行约12-14个月的慢性治疗期，然后要求他们返回进行后续扫描。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The overall purpose of this study is to investigate the involvement of the brain DA system in adults with ADHD and to assess the effects of chronic treatment with the stimulant drug methylphenidate on brain DA function after a 12-14 month treatment period. The hypothesis in the current proposal that postulates compensatory decreases in DAT in ADHD is based on our pilot data in never-medicated ADHD subjects (see Section III). We will follow the research design for PET scanning as we did in IRB #353 in which we successfully enrolled and completed studies in never medicated ADHD subjects. In the current proposal, after the PET scans are completed, the ADHD subjects will return to their referring physician for a chronic treatment period of about 12-14 months and then they will be asked to return for follow-up scanning.